(Bloomberg) -- UnitedHealth Group Inc.’s Oxford unit, which runs health plans in the northeastern U.S., will favor Sanofi and Regeneron Pharmaceuticals Inc.’s new cholesterol-cutting shot over a similar treatment made by Amgen Inc.
Oxford covers about 1.2 million people, according to data compiled by Bloomberg.
Its patients will have to take Sanofi and Regeneron’s injection Praluent for 12 weeks without sufficient effect or have a history of not being able to tolerate the drug before the insurer will cover Amgen’s drug Repatha, the company said in an update posted online. The policy takes effect on Jan. 1.
It’s the latest move by a health insurer or pharmacy benefit manager to limit access to the cholesterol treatments, called PCSK9 inhibitors, that have a list price of about $14,000 a year.
CVS Health Corp. last month signed an exclusive deal with Amgen to cover its drug. By picking one drug over another, insurers and pharmacy benefit managers can gain better prices.
PCSK9 inhibitors are designed to help people with high levels of LDL, or “bad,” cholesterol who can’t get their condition under control with statins such as Pfizer Inc.’s Lipitor.
Payers of insurance benefits have worried they could become one of the costliest drug classes ever, because of their high price and the large number of people in the U.S. with high levels of bad cholesterol.
For now, their scope is more limited to those with genetic conditions or who can’t tolerate other drugs.
Representatives for Amgen, Sanofi and Regeneron didn’t immediately respond to requests for comment.
Copyright 2018 Bloomberg. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
